{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:01:41Z","timestamp":1793754101409,"version":"4.6.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.hoc.2023.05.011","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T14:59:21Z","timestamp":1686841161000},"page":"1201-1214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies"],"prefix":"10.1016","volume":"37","author":[{"given":"Karthik","family":"Nath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hoc.2023.05.011_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"10.1016\/j.hoc.2023.05.011_bib2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.hoc.2023.05.011_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.05.011_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"10.1016\/j.hoc.2023.05.011_bib5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"10343","key":"10.1016\/j.hoc.2023.05.011_bib6","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.hoc.2023.05.011_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10299","key":"10.1016\/j.hoc.2023.05.011_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2023.05.011_bib9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2023.05.011_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2023.05.011_bib11","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2023.05.011_bib12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.05.011_bib13","first-page":"02197","article-title":"Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma","volume":"22","author":"Cliff","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2023.05.011_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2023.05.011_bib15","article-title":"Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy","author":"Al Hadidi","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2023.05.011_bib16","article-title":"Allogeneic BCMA-targeting CAR T\u00a0cells in relapsed\/refractory multiple myeloma: phase 1\u00a0UNIVERSAL trial interim results","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.hoc.2023.05.011_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.05.011_bib18","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2023.05.011_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/d41573-022-00040-2","article-title":"Bispecific antibodies in oncology","volume":"21","author":"Esfandiari","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"24","key":"10.1016\/j.hoc.2023.05.011_bib20","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib21","doi-asserted-by":"crossref","first-page":"10137","DOI":"10.1182\/blood-2022-158146","article-title":"Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study","volume":"140","author":"Dekhtiarenko","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.05.011_bib22","first-page":"2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities","author":"Falchi","year":"2022","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2023.05.011_bib23","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2023.05.011_bib24","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Advances"},{"issue":"7","key":"10.1016\/j.hoc.2023.05.011_bib25","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib26","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1182\/blood-2022-159756","article-title":"MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab\u00a0+ Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma","volume":"140","author":"Zamagni","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.05.011_bib27","first-page":"2022017848","article-title":"Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy","author":"Van Oekelen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.05.011_bib28","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India","author":"Palani","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.hoc.2023.05.011_bib29","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2023.05.011_bib30","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2023.05.011_bib31","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.hoc.2023.05.011_bib32","first-page":"01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"22","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.05.011_bib33","first-page":"00842","article-title":"Ciltacabtagene Autoleucel, an Anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"22","author":"Martin","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.05.011_bib34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.hoc.2023.05.011_bib35","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.hoc.2023.05.011_bib36","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib37","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1182\/blood-2022-166196","article-title":"Real-World Analysis of Cytopenias after Chimeric Antigen Receptor T-Cell Therapy: A Comparison of BCMA and CD19 Based Outcomes","volume":"140","author":"Zhuang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.05.011_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.01.012","article-title":"Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience","author":"Kourelis","year":"2023","journal-title":"Transplantation and cellular therapy"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib39","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2022-156811","article-title":"Pharmacodynamic Effects of Nirogacestat, a Gamma Secretase Inhibitor, on B-Cell Maturation Antigen in Healthy Participants","volume":"140","author":"Shearer","year":"2022","journal-title":"Blood"},{"issue":"485","key":"10.1016\/j.hoc.2023.05.011_bib40","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T\u00a0cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.hoc.2023.05.011_bib41","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T\u00a0cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematology"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib42","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2022-160038","article-title":"Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633\/BMS-986354 in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib43","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1","volume":"140","author":"Cortes-Selva","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib45","doi-asserted-by":"crossref","first-page":"10148","DOI":"10.1182\/blood-2022-160173","volume":"140","author":"Krishnan","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2023.05.011_bib46","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2023.05.011_bib48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5\/CD3 and Is a Requirement for Myeloma Cell Killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib49","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: Early Experience from a Phase I Study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib50","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2022-159381","article-title":"Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity","volume":"140","author":"Trudel","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.011_bib51","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood-2022-166494","article-title":"Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma","volume":"140","author":"Raje","year":"2022","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:22:04Z","timestamp":1760185324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823000667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0889858823000667"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.05.011","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}